康希諾生物-B(06185.HK)上半年扭虧為盈至9.37億元
格隆匯8月28日丨康希諾生物-B(06185.HK)公佈中期業績，截至2021年6月30日止6個月，公司收入主要來自銷售疫苗產品，達人民幣20.61億元，去年同期收入為零；公司所有者應占溢利為人民幣9.37億元，去年同期則虧損為人民幣1.02億元，基本每股盈利為人民幣3.79元。
公司的研發開支由截至2020年6月30日止六個月的約人民幣1.08億元增加至截至2021年6月30日止六個月的約人民幣5.51億元，主要由於(i)研發疫苗的臨牀試驗及測試費增加約人民幣3.80億元；(ii)所用原材料及消耗材料增加約人民幣2230萬元；及(iii)僱員福利開支增加約人民幣1260萬元。
康希諾生物的使命是研發、生產和商業化高質量、創新及經濟實惠的疫苗。肩負此使命的，是公司傑出的創始人和高級管理層團隊，包括多位擁有於全球製藥公司領導創新國際疫苗研發經驗的世界頂尖科學家。其他管理層成員均為來自領先的跨國及國內生物製藥公司的疫苗行業資深人士。
公司的疫苗產品線在戰略上旨在針對龐大且供不應求的全球市場，可總結為三個類別：(i)全球創新疫苗(如我們的Ad5-nCoV、Ad5-EBOV、在研結核病加強疫苗及在研PBPV)，以迎合全球尚未滿足的醫療需求；(ii)潛在的中國首創疫苗，憑藉質量更高的世界級疫苗取代現時的主流疫苗(如我們的在研MCV4及在研DTcP疫苗)；及(iii)與中國市場的進口產品競爭的中國潛在最佳疫苗(如公司的在研PCV13i)。
公司正為13個疾病領域研發16種在研疫苗。自2021年2月以來，公司的Ad5-nCoV已獲墨西哥、巴基斯坦、匈牙利、智利、阿根廷、厄瓜多爾及吉爾吉斯斯坦等境外多個國家的緊急使用授權，並獲國家藥監局於中國的附條件上市許可及馬來西亞的附條件批准。於2021年6月，公司的MCV2已於中國獲得國家藥監局的新藥申請批准。除了公司的Ad5-nCoV、MCV2、MCV4及Ad5-EBOV之外，公司有6種在研疫苗處於臨牀試驗階段或臨牀試驗申請階段。公司亦有6種臨牀前在研疫苗，包括1種在研聯合疫苗。截至公吿日期，除Ad5-nCoV及MCV2外，公司未將任何其他產品商業化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
